FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)

01:00 EDT 11 Oct 2013 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
CIU is a skin condition characterized by red, swollen, itchy hives Currently, H1-antihistamines are the only approved therapy for patients suffering from CIU, also known as chronic spontaneous urticar...

Other Sources for this Article

Genentech
Media Contact:
Chris Vancheri, 650-467-6800
or
Investor Contacts:
Thomas Kudsk Larsen, 650-467-2016
Karl Mahler, 011 41 61 687 8503

NEXT ARTICLE

More From BioPortfolio on "FDA Files Genentech’s Supplemental Biologics License Application of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU)"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Allergies
Latest News Clinical Trials Research Drugs Reports Corporate
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Advertisement

Searches Linking to this Story